Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pyridoxine phosphate (PNP) is a phosphorylated form of pyridoxine, a B6 vitamer, and serves as a crucial intermediate in the vitamin B6 metabolic pathway. It is a direct precursor to pyridoxal phosphate (PLP), the active coenzyme form of vitamin B6, which is essential for numerous enzymatic reactions, particularly in neurotransmitter synthesis. PNP levels are tightly regulated, as it can inhibit PLP-dependent enzymes. It is converted to PLP by enzymes such as pyridoxine phosphate oxidase (PNPO) and pyridoxine/pyridoxamine phosphate oxidase (PPOX), and can be dephosphorylated by phosphatases like pyridoxal phosphatase and YigL. Therapeutically, it is used to address conditions related to impaired PLP synthesis, such as certain forms of epilepsy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pyridoxine phosphate.